Last reviewed · How we verify
valent pneumococcal conjugated vaccine
At a glance
| Generic name | valent pneumococcal conjugated vaccine |
|---|---|
| Sponsor | The HIV Netherlands Australia Thailand Research Collaboration |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs (PHASE4)
- Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination (PHASE3)
- Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine (PHASE2)
- Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49 (PHASE3)
- A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant (PHASE1)
- A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six Months
- A Study to Learn More About Prevenar 20 Once it is Out in the Korean Market
- A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: